In a preclinical study, the activity of the high affinity anti-PRLR IgG1 antibody REGN2878-DM1 was evaluated, which induced a potent cell-cycle arrest and cytotoxicity in PRLR-expressing tumor cell lines. The gene discussed is PRLR; the disease is neoplasm.